Bacil Pharma has scheduled its 39th annual general meeting for September 23, 2026, to approve a significant increase in authorized share capital and key leadership changes. The board also confirmed no dividend for FY26.

The meeting will be conducted via video conferencing or other audio-visual means (VC/OAVM) in compliance with Ministry of Corporate Affairs and SEBI circulars. The register of members and share transfer books will remain closed from September 17 to September 23, 2026. Members holding shares as on the cut-off date of September 18, 2026, are eligible to vote through remote e-voting facilitated by NSDL.

Board Meeting Outcomes

The board approved several key resolutions during its meeting on August 29, 2026. The primary focus was on corporate governance matters and structural adjustments to the company’s capital base.

Leadership Changes

A notable development is the proposed change in designation of Chaitali Kalpataru Shah. The board seeks shareholder approval to elevate her role from Executive Director to Managing Director, effective August 25, 2026. This change requires a special resolution at the upcoming AGM. She will hold office until July 28, 2029.

Additionally, the board appointed two new directors on August 25, 2026: Anil Singh as Non-Executive Director and Mahesh Singh as Non-Executive Independent Director. Their appointments are subject to regularization by shareholders at the AGM. The board also seeks re-appointment of Omprakash Pyarelal Sonar and Vivek Mukesh Yadav as Non-Executive Independent Directors. Ms. Shah retires by rotation at this AGM and offers herself for re-appointment as a director.

Financial Performance: Other Income Drives PBT

For FY26, Bacil Pharma reported zero revenue from operations, consistent with FY25. However, total revenue rose to ₹123.52 lakh from ₹66.14 lakh in the prior year, driven entirely by other income. Profit before tax more than doubled to ₹99.02 lakh from ₹40.76 lakh. Despite this operational profitability, the company reported a net loss after tax of ₹61.88 lakh, compared to a profit of ₹40.05 lakh in FY25.

The reversal from profit to loss was primarily due to other comprehensive income (OCI) losses of ₹217.43 lakh, arising from fair value adjustments on investments. In contrast, OCI loss in FY25 was minimal at ₹0.36 lakh.

What the Numbers Show

The divergence between profit before tax and net loss highlights the company’s current reliance on non-operational activities. With zero revenue from core pharmaceutical operations, the business model remains investment-driven. The significant OCI loss indicates volatility in the fair value of its financial assets, which currently stand at ₹2,424 lakh on the balance sheet. While cost control measures kept expenses down to ₹24.50 lakh, the lack of operational cash flow generation remains a key structural characteristic of the company’s current financial profile.

Capital Structure Adjustment

The company proposes to increase its authorized share capital from ₹20 crore (2 crore equity shares) to ₹70 crore (7 crore equity shares). Each share has a face value of ₹10. The new shares will rank pari passu with existing equity shares. This move aims to broaden the capital structure and meet future funding requirements.

Auditor Appointment

The board recommends the appointment of M/s Sarang Shivajirao Chavan & Associates Chartered Accountants as statutory auditors. If approved, they will hold office from the conclusion of the 39th AGM until the conclusion of the 43rd AGM. This replaces the previous auditors, Laxmikant Kabra & Co LLP, who resigned in August 2025.

Bacil Pharma Limited appointed Mahesh Singh as an additional independent director and Anil Shiv Charan Singh as an additional non-executive director on August 25, 2026. The appointments require shareholder approval.

The board approved the appointments during a meeting held on Tuesday, August 25, 2026. Both directors have submitted necessary declarations under the Companies Act, 2013 and SEBI LODR Regulations. They are not debarred from holding office by any regulatory authority.

Director Profiles

Mahesh Singh brings over seven years of experience in the trading industry. His expertise includes product sales, brand establishment, and online sales strategies. The company cited his experience in accounting and financial matters as the reason for his appointment.

Anil Shiv Charan Singh has experience in business management and commercial activities. His background includes commodity trading and related business operations. The board noted his business acumen would contribute to strategic decision-making.

Regulatory Compliance

The appointments comply with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Detailed disclosures are enclosed in Annexure A of the filing. Neither director is related to any existing director of the company.